<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0005">
 <label>Table 1</label>
 <caption>
  <p>The possible strengths and weaknesses of different types of vaccination strategies against SARS-CoV and MERS-CoV.</p>
 </caption>
 <alt-text id="al0010">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Vaccines strategies</th>
    <th>Vaccine candidates</th>
    <th>Phase</th>
    <th>Advantages</th>
    <th>Disadvantages</th>
    <th>Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="2">Nucleotide based</td>
    <td>
     <bold>DNA vaccines</bold>
     <break/>
     <break/>S, M and N genes
    </td>
    <td>Phase I,II (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT03721718" id="ir0005" xmlns:xlink="http://www.w3.org/1999/xlink">NCT03721718</ext-link>)
    </td>
    <td>Simple, stable, safe and easy to produce, cost-effective; induce neutralizing antibodies; human monoclonal antibodies and cytotoxic T-lymphocyte response</td>
    <td>Lower immunogenicity as compared to inactivated and live-attenuated virus vaccines; require any additional administration device</td>
    <td>[
     <xref rid="bb0115" ref-type="bibr">23</xref>,
     <xref rid="bb0180" ref-type="bibr">36</xref>,
     <xref rid="bb0195" ref-type="bibr">39</xref>,
     <xref rid="bb0235" ref-type="bibr">47</xref>,
     <xref rid="bb0240" ref-type="bibr">48</xref>]
    </td>
   </tr>
   <tr>
    <td>
     <bold>mRNA vaccines</bold>
     <break/>
     <break/>mRNA-1273 and BNT162
     <break/>encoding S protein
    </td>
    <td>Phase I (mRNA-1273) and preclinical (BNT162)</td>
    <td>Easy to design; manufacturing is a comparably short, simple, rapid and cost-effective; avoid the risk of host genomic integration; safer than inactivated or protein based vaccines as they are free from the risk of protein contamination or the injected virus to become active; induce both humoral and cellular immune responses</td>
    <td>Unprotected naked mRNA alone is not very stable thus requires highly efficient carriers to stabilize and pack the mRNA into an injectable form</td>
    <td>[
     <xref rid="bb0130" ref-type="bibr">26</xref>,
     <xref rid="bb0135" ref-type="bibr">27</xref>,
     <xref rid="bb0260" ref-type="bibr">52</xref>]
    </td>
   </tr>
   <tr>
    <td>Subunit vaccine</td>
    <td>Spike glycoproteins (S), membrane proteins (M), nucleoproteins (N)</td>
    <td>Preclinical</td>
    <td>High safety profile; less prone to generate the side effects at the site of inoculation; involving pure antigens that only includes synthetic peptides or recombinant proteins that expresses only particular fragments of immunogen; consistent production; eliciting T and B cell mediated immunity</td>
    <td>Require appropriate adjuvant; cost-effectiveness may vary; lower immunogenicity</td>
    <td>[
     <xref rid="bb0120" ref-type="bibr">24</xref>,
     <xref rid="bb0245" ref-type="bibr">49</xref>,
     <xref rid="bb0315" ref-type="bibr">63</xref>,
     <xref rid="bb0335" ref-type="bibr">67</xref>]
    </td>
   </tr>
   <tr>
    <td>Recombinant vector vaccines</td>
    <td>Coronavirus proteins/glycoproteins expressed by attenuated adenovirus/poxvirus/Newcastle disease virus</td>
    <td>Phase I (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT03399578" id="ir0010" xmlns:xlink="http://www.w3.org/1999/xlink">NCT03399578</ext-link>, 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT03615911" id="ir0015" xmlns:xlink="http://www.w3.org/1999/xlink">NCT03615911</ext-link>)
    </td>
    <td>Quickly constructed; Efficient in inducing immune response; ease of administration and production; elicit long-termed cell mediated and humoral immunity</td>
    <td>Restricted cloning ability, limited host range and pre-existent immunity; route of administration that manifest different immune response; possible Th2-bias</td>
    <td>[
     <xref rid="bb0415" ref-type="bibr">83</xref>,
     <xref rid="bb0420" ref-type="bibr">84</xref>,
     <xref rid="bb0430" ref-type="bibr">86</xref>,
     <xref rid="bb0465" ref-type="bibr">93</xref>,
     <xref rid="bb0500" ref-type="bibr">100</xref>]
    </td>
   </tr>
   <tr>
    <td>Attenuated vaccines</td>
    <td>Gene deletion of various essential genes (S,N,E genes), nonstructural proteins (nsp) encoding genes</td>
    <td>Preclinical</td>
    <td>Persists for longer period of time, showcases the entire viral antigens complement to the host immune system, efficient in generating a strong cytotoxic T-cell response</td>
    <td>Risk of reversion to its virulent form; requirement of cold chain; not appropriate for infants, immunocompromised or elderly individuals</td>
    <td>[
     <xref rid="bb0530" ref-type="bibr">106</xref>,
     <xref rid="bb0550" ref-type="bibr">110</xref>]
    </td>
   </tr>
   <tr>
    <td>Inactivated virus vaccines</td>
    <td>Inactivated or whole killed virus (WKV)</td>
    <td>Preclinical</td>
    <td>Rapid development; efficient in inducing immunity and protection against virus infection; efficiently neutralizes induction of antibody; can be formulated with different adjuvant</td>
    <td>Hypersensitivity
     <break/>Th2-bias
    </td>
    <td>[
     <xref rid="bb0445" ref-type="bibr">89</xref>,
     <xref rid="bb0450" ref-type="bibr">90</xref>,
     <xref rid="bb0625" ref-type="bibr">125</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
